Discover
HELP
Cybin D/B/A Helus Pharma
11.80
2 x 6.79
2 x 11.87
bid
ask
+
1.08
10.07%
2 @ 07:59 PM
11.95 +0.15 (1.27%)
| Ytd | 44.25% | |
| 1y | 88.20% |
10.45
day range
12.09
3.87
52 week range
14.02
| Open | 10.71 | Prev Close | 10.72 | Low | 10.45 | High | 12.09 | Mkt Cap | 862.22M |
| Vol | 1.66M | Avg Vol | 1.77M | EPS | -4.15 | P/E | N/A | Forward P/E | -7.55 |
| Beta | 0.63 | Short Ratio | 1.59 | Inst. Own | 41.29% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 11.91 | 200-d Avg | 7.49 | 1yr Est | 40.24 |
| Income Statement | |||
| Operating Expenses | 49.08M | ||
| Research and Development Expense | 30.76M | ||
| Selling, General and Administrative Expense | 6.75M | ||
| Operating Income | -49.08M | ||
| Net Income | -47.82M | ||
| Net Income Common Stock | -47.82M | ||
| Net Income Common Stock (USD) | -33.68M | ||
| Consolidated Income | -47.82M | ||
| Earnings per Basic Share | -0.91 | ||
| Earnings per Basic Share (USD) | -0.64 | ||
| Earnings per Diluted Share | -0.91 | ||
| Earning Before Interest & Taxes (EBIT) | -47.82M | ||
| Earning Before Interest & Taxes (USD) | -33.68M | ||
| Weighted Average Shares | 52.32M | ||
| Weighted Average Shares Diluted | 52.32M | ||
| Balance Sheet | |||
| Cash and Equivalents | 166.37M | ||
| Cash and Equivalents (USD) | 117.16M | ||
| Trade and Non-Trade Receivables | 5.04M | ||
| Current Assets | 192.70M | ||
| Property, Plant & Equipment Net | 180.00K | ||
| Total Assets | 259.65M | ||
| Current Liabilities | 17.57M | ||
| Total Liabilities | 17.57M | ||
| Accumulated Retained Earnings (Deficit) | -437.35M | ||
| Accumulated Other Comprehensive Income | 640.00K | ||
| Shareholders Equity | 242.09M | ||
| Shareholders Equity (USD) | 170.48M | ||
| Assets Non-Current | 66.96M | ||
| Goodwill and Intangible Assets | 66.78M | ||
| Trade and Non-Trade Payables | 17.57M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 31.00K | ||
| Net Cash Flow from Financing | 46.53M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 9.11M | ||
| Capital Expenditure | -320.00K | ||
| Issuance (Purchase) of Equity Shares | 46.53M | ||
| Net Cash Flow from Investing | -320.00K | ||
| Net Cash Flow from Operations | -37.07M | ||
| Effect of Exchange Rate Changes on Cash | -36.00K | ||
| Share Based Compensation | 11.57M | ||